Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Ascierto, Maria L ^a,b,i   Worschech, Andrea ^a,c,f   Yu, Zhiya ^d   Adams, Sharon ^e   Reinboth, Jennifer ^a,c,f   Chen, Nanhai G ^c,l   Pos, Zoltan ^a   Roychoudhuri, Rahul ^d   Di Pasquale, Giovanni ^g   Bedognetti, Davide ^a,b,j   Uccellini, Lorenzo ^a,k   Rossano, Fabio ^h   Ascierto, Paolo A ⁱ   Stroncek, David F ^a   Restifo, Nicholas P ^d   Wang, Ena ^a   Szalay, Aladar A ^c,f,l   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c GENELUX CORPORATION   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j UNIVERSITY OF GENOA   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; ONCOLYTIC VIRUS;

ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; ONCOLYTIC VIROTHERAPY; PHENOTYPE; PREDICTION; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION; VIRUS REPLICATION; CELL STRAIN HT29; CLUSTER ANALYSIS; CULTURE MEDIUM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE VECTOR; PHYSIOLOGY; REPORTER GENE; TUMOR CELL LINE; VIRAL TROPISM;

CELL LINE, TUMOR; CLUSTER ANALYSIS; CULTURE MEDIA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; GENETIC VECTORS; HT29 CELLS; HUMANS; ONCOLYTIC VIRUSES; TRANSCRIPTION, GENETIC; VACCINIA VIRUS; VESICULOVIRUS; VIRAL TROPISM; VIRUS REPLICATION;

EID: 80054110110     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-451     Document Type: Article

References (36)

1. Thorne SH, Bartlett DL, Kirn DH. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally?. Curr Gene Ther 2005, 5(4):429-443. 10.2174/1566523054546215, 16101516.
2. Mastrangelo MJ, Eisenlohr LC, Gomella L, Lattime EC. Poxvirus vectors: orphaned and underappreciated. J Clin Invest 2000, 105(8):1031-1034. 10.1172/JCI9819, 300840, 10772644.
3. O'Shea CC. DNA tumor viruses -- the spies who lyse us. Curr Opin Genet Dev 2005, 15(1):18-26. 10.1016/j.gde.2004.12.010, 15661529.
4. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252(5007):854-856. 10.1126/science.1851332, 1851332.
5. Weibel S, Raab V, Yu YA, Worschech A, Wang E, Marincola FM, Szalay AA. Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 2011, 11:68. 10.1186/1471-2407-11-68, 3044654, 21320309.
6. Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM, Szalay AA. The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother 2009, 58(9):1355-1362. 10.1007/s00262-009-0686-7, 19266198.
7. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007, 67(20):10038-10046. 10.1158/0008-5472.CAN-07-0146, 17942938.
8. Sanchez-Puig JM, Sanchez L, Roy G, Blasco R. Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol J 2004, 1:10. 10.1186/1743-422X-1-10, 535549, 15555076.
9. Kelly KJ, Woo Y, Brader P, Yu Z, Riedl C, Lin SF, Chen N, Yu YA, Rusch VW, Szalay AA, et al. Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma. Hum Gene Ther 2008, 19(8):774-782. 10.1089/hum.2008.036, 2940611, 18754710.
10. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA, et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab 2008, 93(11):4403-4407. 10.1210/jc.2008-0316, 18697871.
11. Yu Z, Li S, Brader P, Chen N, Yu YA, Zhang Q, Szalay AA, Fong Y, Wong RJ. Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Cancer 2009, 8:45. 2714037, 19580655.
12. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, Weibel S, Raab V, Sabatino M, Monaco A, Liu H, et al. Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 2009, 10:301. 10.1186/1471-2164-10-301, 2713268, 19583830.
13. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003, 63(24):8634-8647.
14. Weinstein JN, Pommier Y. Transcriptomic analysis of the NCI-60 cancer cell lines. C R Biol 2003, 326(10-11):909-920. 10.1016/j.crvi.2003.08.005, 14744097.
15. Weinstein JN. Integromic analysis of the NCI-60 cancer cell lines. Breast Dis 2004, 19:11-22.
16. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Ajay, Kouros-Mehr H, Fridlyand J, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006, 5(4):853-867. 10.1158/1535-7163.MCT-05-0155, 2733874, 16648555.
17. Weinstein JN. Spotlight on molecular profiling: "Integromic" analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 2006, 5(11):2601-2605. 10.1158/1535-7163.MCT-06-0640, 17088435.
18. Sabatino M, Zhao Y, Voiculescu S, Monaco A, Robbins P, Karai L, Nickoloff BJ, Maio M, Selleri S, Marincola FM, et al. Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res 2008, 68(1):122-131. 10.1158/0008-5472.CAN-07-1939, 18172304.
19. Monsurro V, Beghelli S, Wang R, Barbi S, Coin S, Di Pasquale G, Bersani S, Castellucci M, Sorio C, Eleuteri S, et al. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J Transl Med 2010, 8:10. 10.1186/1479-5876-8-10, 2845551, 20113473.
20. Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, Morse HC, Stroncek D, Marincola FM. HLA class I and II genotype of the NCI-60 cell lines. J Transl Med 2005, 3(1):11. 10.1186/1479-5876-3-11, 555742, 15748285.
21. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002, 76(2):895-904. 10.1128/JVI.76.2.895-904.2002, 136833, 11752178.
22. Krausa P, Browning MJ. A comprehensive PCR-SSP typing system for identification of HLA-A locus alleles. Tissue Antigens 1996, 47(3):237-244. 10.1111/j.1399-0039.1996.tb02547.x, 8740775.
23. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000, 18(4):457-459. 10.1038/74546, 10748532.
24. Wang E. RNA amplification for successful gene profiling analysis. J Transl Med 2005, 3:28. 10.1186/1479-5876-3-28, 1201175, 16042807.
25. Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurro V, Smith K, Hu N, Su H, Taylor PR, et al. Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics 2004, 5(1):55. 10.1186/1471-2164-5-55, 516027, 15310404.
26. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007, 3:11-17. 2675854, 19455231.
27. Seubert CM, Stritzker J, Hess M, Donat U, Sturm JB, Chen N, von Hof JM, Krewer B, Tietze LF, Gentschev I, et al. Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a beta-galactosidase-activatable prodrug seco-analog of duocarmycin SA. Cancer Gene Ther 2011, 18(1):42-52. 10.1038/cgt.2010.49, 3007590, 20829890.
28. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003, 9(10):1306-1312. 10.1038/nm929, 14502277.
29. Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, Brinkkoetter P, Moller T, Wildner O, Pesonen S, et al. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res 2009, 69(12):5115-5125. 10.1158/0008-5472.CAN-09-0645, 2738419, 19491256.
30. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005, 6(10):801-811. 10.1038/nrm1736, 16314869.
31. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73(2):309-319. 10.1016/0092-8674(93)90231-E, 8477447.
32. Wang K, Guan T, Cheresh DA, Nemerow GR. Regulation of adenovirus membrane penetration by the cytoplasmic tail of integrin beta5. J Virol 2000, 74(6):2731-2739. 10.1128/JVI.74.6.2731-2739.2000, 111763, 10684289.
33. Lyle C, McCormick F. Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells. Virol J 2010, 7:148. 10.1186/1743-422X-7-148, 2909962, 20615244.
34. de Parseval A, Lerner DL, Borrow P, Willett BJ, Elder JH. Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding. J Virol 1997, 71(8):5742-5749. 191826, 9223460.
35. Loffler S, Lottspeich F, Lanza F, Azorsa DO, ter Meulen V, Schneider-Schaulies J. CD9, a tetraspan transmembrane protein, renders cells susceptible to canine distemper virus. J Virol 1997, 71(1):42-49. 191022, 8985321.
36. Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA 2000, 97(23):12705-12710. 10.1073/pnas.230436397, 18828, 11058167.